Glenmark Pharmaceuticals USA to launch Potassium Phosphates Injection USP in multiple vial sizes

The product is bioequivalent and therapeutically equivalent to Fresenius Kabi’s reference drug (NDA 212832)

Glenmark Pharmaceuticals Inc., USA, is launching its Potassium Phosphates Injection USP in March 2026. Available in 5 mL and 15 mL single-dose vials, as well as 50 mL pharmacy bulk packages, the product is bioequivalent and therapeutically equivalent to Fresenius Kabi’s reference drug (NDA 212832).

According to IQVIA sales data for the 12-month period ending January 2026, the Potassium Phosphates Injection USP, 15 mmol P / 22 mEq K per 5 mL, 45 mmol P / 66 mEq K per 15 mL, and 150 mmol P / 220 mEq K per 50 mL market2 achieved annual sales of approximately $50.7 million.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, “We look forward to growing our portfolio of products within the institutional channel with the upcoming launch of Potassium Phosphates Injection USP, 15 mmol P / 22 mEq K per 5 mL and 45 mmol P / 66 mEq K per 15 mL Single-Dose Vials and 150 mmol P / 220 mEq K per 50 mL Pharmacy Bulk Package Vials. We continue to strengthen our commitment to bring quality and affordable alternatives to market for patients in need with each injectable launch.”